Valorie J Bell, NP | |
2500 Jacksboro Pike, Suite 6, Jacksboro, TN 37757-2818 | |
(423) 907-1685 | |
(423) 907-1688 |
Full Name | Valorie J Bell |
---|---|
Gender | Female |
Speciality | Clinical Nurse Specialist - Women's Health |
Location | 2500 Jacksboro Pike, Jacksboro, Tennessee |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1710983895 | NPI | - | NPPES |
3909399 | Medicaid | TN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
364SW0102X | Clinical Nurse Specialist - Women's Health | APN11852 (Tennessee) | Primary |
Mailing Address | Practice Location Address |
---|---|
Valorie J Bell, NP 2500 Jacksboro Pike, Suite 6, Jacksboro, TN 37757-2818 Ph: (423) 907-1685 | Valorie J Bell, NP 2500 Jacksboro Pike, Suite 6, Jacksboro, TN 37757-2818 Ph: (423) 907-1685 |
News Archive
Key to the future efficiency of the United States' health care system is effective implementation of new technologies, such as electronic medical records, as well as dovetailing those technologies with the human care and decision-making that is so critical to good medicine.
Autism, a neurodevelopment disorder which has increased tenfold over the last 15 years, now affects 30 of every 10,000 children in the United States.
Hospitals vary in management of children with traumatic brain injury—particularly in monitoring and preventing the harmful effects of increased intracranial pressure (ICP), according to a study in the November issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
University of Otago researchers have discovered one of the reasons why more than 50 per cent of people with type 2 diabetes die from heart disease.
BeiGene (Beijing), Co., Ltd., today announced dose administration for the first patient in a Phase 1 study of BGB-283 in patients with B-RAF or K-RAS mutations. BGB-283 is an investigational, oral, selective, potent second generation inhibitor of B-RAF, making it a targeted therapeutic candidate to potentially treat and bring benefit to patients with cancers that harbor BRAF mutations and/or aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway.
› Verified 9 days ago